NR4A1 and lymphoma: NR4A1 was identified as an oncogenic driver in pancreatic, renal, lung and colon cancers.28, 29 Several other studies have reported that NR4A1 was a tumour suppressor in lymphoma, triple‐negative breast cancer and hepatocellular carcinoma.32, 33 The expression and nuclear accumulation of NR4A1 confer chemotherapeutic resistance in some types of cancer.